Drug intelligence / Profile preview

CD45RA-depleted peripheral blood mononuclear cells

Development stage
Phase 2
Lead developer
Miltenyi Biotec
Modality
Vaccines & Immunotherapeutics, Cell Therapies
Administration
Intravenous
01

Overview

CD45RA-depleted peripheral blood mononuclear cells are a specialized cellular therapy product created by selectively removing CD45RA-positive cells (primarily naive T cells) from donor peripheral blood mononuclear cells (PBMCs), resulting in a preparation enriched with memory T cells that can fight infections while reducing the risk of graft-versus-host disease (GVHD). ## Description CD45RA-depleted peripheral blood mononuclear cells are a cellular therapy product created through immunomagnetic depletion of CD45RA-positive cells from donor peripheral blood mononuclear cells. This selective depletion process removes naive T cells (TN) while preserving memory T cells (TM) that have specificity for common opportunistic pathogens[1][6]. The resulting cellular product contains a high amount of memory T cells that can provide protection against viral infections (such as cytomegalovirus, Epstein-Barr virus, and adenovirus) and fungal infections (such as Aspergillus)[5][7]. This approach has been shown to enhance early T-cell recovery and significantly reduce both the incidence and duration of viremia in transplant recipients[1]. The depletion process is performed using GMP-grade murine αCD45RA monoclonal antibody directly conjugated to Miltenyi iron dextran beads, which allows for the selective removal of CD45RA+ cells while preserving CD34+ hematopoietic stem cells and functional memory T cells[7]. Clinical studies have demonstrated that recipients of CD45RA-depleted grafts had significantly higher T-cell counts at Day +30 post-transplant (550/μL vs 10/μL) and higher T-cell diversity compared to recipients of conventional T-cell depleted grafts[1]. This approach has been particularly valuable in the context of haploidentical hematopoietic cell transplantation, where it provides a safer alternative to conventional T-cell depletion methods[1][5].

Other names
CD45RA-depleted donor T lymphocytesCD-45RA-depleted donor T lymphocytesCD 45RA-depleted donor T lymphocytesCD45RA-depleted PBMCsCD-45RA-depleted PBMCsCD 45RA-depleted PBMCsCD45RA-depleted T cellsCD-45RA-depleted T cellsCD 45RA-depleted T cellsCD45RA- T cellsCD-45RA- T cellsCD 45RA- T cellsmemory T cell-enriched donor lymphocytes
02

Targets

MHC I (MHC class I})

Beyond the preview

Go deeper on CD45RA-depleted peripheral blood mononuclear cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD45RA-depleted peripheral blood mononuclear cells.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call